High dose flaxseed oil supplementation may affect fasting blood serum glucose management in human type 2 diabetics

Journal of Oleo Science

Volumn 57, Issue 5, 2008, Pages 269-273

  Barre, Douglas E ^a   Mizier Barre, Kazimiera A ^a   Griscti, Odette ^a   Hafez, Kevin ^b  

^a CAPE BRETON UNIVERSITY   (Canada)

^b KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

Fasting serum glucose; Flaxseed oil; HbA1c; Human; Insulin; Type 2 diabetes

Indexed keywords

FATTY ACID; INSULIN; LINOLENIC ACID; LINSEED OIL; PLACEBO; SAFFLOWER OIL;

ARTICLE; BLOOD; CHEMISTRY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DIET SUPPLEMENTATION; DOSE RESPONSE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MALE; METABOLISM; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL;

ALPHA-LINOLENIC ACID; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIETARY SUPPLEMENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FASTING; FATTY ACIDS; FEMALE; HUMANS; INSULIN; LINSEED OIL; MALE; MIDDLE AGED; PLACEBOS; SAFFLOWER OIL;

EID: 43149109723     PISSN: 13458957     EISSN: 13473352     Source Type: Journal    
DOI: 10.5650/jos.57.269     Document Type: Article

References (33)

1. Alberti, K.; Zimmet, P. Definition, diagnosis, and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabet Med. 15, 1539-553 (1998).
2. Lebovitz, H. Insulin resistance-a common link between type 2 diabetes and cardiovascular disease. Diab. Obes. Metab. 8, 237-249 (2006).
3. Reaven, G. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37, 1595-1607 (1988).
4. Ferrannini, E. Insulin resistance versus insulin deficiency in non-insulin-dependent diabetes mellitus: Problems and prospects. Endocrine Rev. 19, 477-490 (1998).
5. Liese, A.; Schulz M.; Fang, F.; Wolever, T.; D'Agostino, R.; Sparks, K.; Mayer-Davis, E. Dietary glycemic index and glycemic load, carbohydrate and fiber intake and measures of insulin sensitivity, secretion and adiposity in the insulin resistance atherosclerosis study. Diabetes Care 28, 2832-2838 (2005).
6. Hennige, A.; Burks, D.; Ozcan, U.; Kulkarni, R.; Ye, J.; Park, S.; Schubert, M.; Fisher, T.; Dow, M.; Leshan, R.; Zakaria, M.; Mossa-Basha, M.; White, M. Upregulation of insulin receptor substrate-2 in pancreatic B cells prevents diabetes. J. Clin. Invest. 112, 1521-1532 (2003).
7. Roehrich M-E.; Mooser, V.; Lenain, V.; Herz, J.; Nimf, J.; Azhar, S.; Bideau, M.; Capponi, A.; Nicod, P.; Haefliger, J.-A.; Waeber, G. Insulin secreting β-cell dysfunction induced by human lipoproteins. J. Biol. Chem. 278, 18368-18375 (2003).
8. Perseghin, G.; Petersen, K.; Shulman, G. Cellular mechanism of insulin resistance: potential links with inflammation. Int. J. Obesity 27 (Suppl 3), S6-S11 (2003).
9. Rewers, M.; Zaccaro, D.; D'Agostino, R.; Haffner, S.; Saad, M.; Selby, J.; Bergman, R.; Savage, P. Insulin sensitivity, insulinemia and coronary artery disease. The insulin atherosclerosis study. Diabetes Care 27, 781-787(2004).
10. Hanson, R.; Pratley, R.E.; Bogardus, C.; Narayan, K.; Roumain, J.; Imperatore, G.; Fagot-Campagna, A.; Pettitt, D.; Bennett, P.; Knowler, W. Evaluation of simple indices of insulin sensitivity and insulin secretion for use in epidemiologic studies. Am. J. Epid. 151(2). 190-198(2000).
11. Taniguchi, A.; Fukushima, M.; Sakai, M.; Kataoka, K.; Nagata, I.; Doi, K.; Arakawa, H.; Nagasaka, S.; Tokuyama, K.; Yoshikatsu, N. The role of body mass index and triglyceride levels in identifying insulin-sensitive and insulin resistant variant in Japanese non-insulin dependent diabetic patients. Metabolism 49, 1001-1005 (2000),
12. Cefalo, W. Insulin resistance. Cellular and clinical concepts Exp. Biol. Med. 226, 13-26 (2001).
13. Polonsky, K. Dynamics of insulin secretion in obesity and diabetes, Int. J. Obesity 24(Suppl 2), S29-S31 (2000).
14. Rett, K. The relation between insulin resistance and cardiovascular complications of the insulin resistance syndrome. Diab. Obes. Metab. 1(Suppl 1), S8-S16 (1999).
15. Groop, L. Insulin resistance: the fundamental trigger of type 2 diabetes. Diab Obes Metab. 1(Suppl 1), S1-S7 (1999).
16. Jesudason D.; Leong, D.; Dunstan, K.; Wittert, G. Macrovascular risk and diagnostic criteria for type 2 diabetes. Implications for the use of FPG and HbA1c for cost-effective screening. Diabetes Care 26, 485-490 (2003).
17. Chen, H-S.; Chen, R-L.; Jap T-S.; Lin, H-D. A prospective study of glycemic control during holiday time in type 2 diabetic patients. Diabetes Care 27, 326-330 (2004).
18. Lapolla, A.; Tubaro, M.; Reitano, R.; Arico, N.; Ragazzi, E.; Seragalia, R.; Vogliardi, S.; Traldi, P.; Fedele, D. The complexity of non-enzymatic glycation product sets of human globins. Diabetologia 47, 1712-1715 (2004).
19. Mentink, C.; Kilhovd, B.; Rondas-Colbers, G.; Torjesen, P.; Wolffenbuttel, B. Time course of specific AGEs during optimised glycaemic control in type 2 diabetes. Netherlands J. Med. 64, 10-16 (2006).
20. Glauber, H.; Wallace, P.; Griver, K. et al. Adverse metabolic effect of omega-3 fatty acids in non-insulin-dependent diabetes mellitus. Ann. Intl. Med. 108, 663-668(1998).
21. Nettleton, J.; Katz, R. n-3 long-chain polyunsaturated fatty acids in type 2 diabetes: A review. J. Am. Dietetic Assoc. 105 428-440 (2005).
22. Woodman, R.; Mori T.; Burke V. et al. Effects of purified eicosapentaenoic and docosahexaenoic acids on glycemic control, blood pressure and serum lipids in type 2 diabetic patients with treated -hypertension. Am. J. Clin. Nutr. 76, 1007-1015 (2002).
23. Rivellese, A.; Annuzi, G.; Maffettone, A. et al. Longterm effects of fish oil on insulin resistance and plasma lipoproteins in NIDDM patients with hypertriglyceridemia. Diabetes Care 19, 1207-1213 (1996).
24. Nakamura, N.; Hamazaki, T.; Kobayashi, M. et al. Effects of eicosapentaenoic acids on remnant like particles, cholesterol concentrations and plasma fatty acid composition in patients with diabetes mellitus. In vivo 12, 311-314 (1998).
25. Montori, V.; Wollan, P.; Farmer, A.; Dinneen, S. Fish oil supplementation in type 2 diabetes. Diabetes Care 23, 1407-1415 (2000).
26. McManus R.; Clandinin, M.; Jumpson, J. et al. A comparison of the effects of n-3 fatty acids from linseed oil and fish oil in well-controlled type 2 diabetes. Diabetes Care 19, 463-467 (1996).
27. Goh, Y.; Jumpsen, J.; Ryan, E.; Clandinin, M. Effect of α3 fatty acid on plasma lipids, cholesterol and fatty acid content in NIDDM patients. Diabetologia 40, 45-52 (1997).
28. Barre. D.; Griscti, O.; Mizier-Barre, K.; Hafez, K. Flaxseed oil and lipoprotein (a) significantly increase bleeding time in type 2 diabetes patients in Cape Breton, Nova Scotia, Canada. J. Oleo Sci. 54, 347-354 (2005a).
29. Barre, D.; Griscti, O.; Mizier-Barre, K.; Hafez, K. The mechanism by which flaxseed oil consumption increases bleeding time in patients with type 2 diabetes in Cape Breton, Nova Scotia, Canada is independent of lipoprotein (a) concentration. J. Oleo Sci. 54, 617-625 (2005).
30. Ellis, G.; Diamandis, E.; Giesbrect, E.; Daneman, D.; Allen, L. An automated high pressure liquid-chromatographic assay for haemoglobin. A1c. Clin. Chem. 1746-1752 (1984).
31. Roscoe, J.T. Fundamental research statistics for the behavioral sciences. 2nd ed. Holt, Reinhart and Winston, Montreal. 217 (1975).
32. Klein-Platat, C.; Drai, J.; Oujaa, M. et al. Plasma fatty acid composition is associated with the metabolic syndrome and low-grade inflammation in overweight adolescents. Am. J. Clin. Nutr. 82, 1178-1184 (2005).
33. Phinney, S. Fatty acids, inflammation, and the metabolic syndrome. Am. J. Clin. Nutr. 82, 1151-1152 (2005).